IBEX 35
10.901,60 +47,20 (+0,43%) Euro Stoxx 50
4.910,65 -10,57 (-0,21%) Dólar/Euro
1,0703 -0,0015 (-0,14%) Petróleo Brent
83,98 +0,54 (+0,65%) Oro
2.309,50 -1,50 (-0,06%) Bitcoin EUR
54.433,07 +692,20 (+1,29%)
Intra-Cellular Therapies, Inc. (ITCI)
Después del cierre:
Intra-Cellular Therapies, Inc.
430 East 29th Street
New York, NY 10016
United States
646 440 9333
https://www.intracellulartherapies.com
Sector(es): Healthcare
Sector: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 610
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Sharon Mates Ph.D. | Co-Founder, Chairman & CEO | 2,23M | 1,99M | 1953 |
| Mr. Michael I. Halstead J.D. | President | 983,65k | 1,91M | 1973 |
| Dr. Suresh K. Durgam M.D. | Executive VP & Chief Medical Officer | 961,84k | N/A | 1969 |
| Mr. Mark Neumann | EVP & Chief Commercial Officer | 998,36k | 4,46M | 1963 |
| Dr. Robert E. Davis Ph.D. | Senior VP & Chief Scientific Officer | 646,12k | N/A | 1951 |
| Mr. Juan Fernando Sanchez | Vice President of Corporate Communications & Investor Relations | 296,75k | N/A | 1971 |
| Ms. Karen Patruno Sheehy Esq. | Senior VP & Chief Compliance Officer | N/A | N/A | 1962 |
Descripción
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.
Gobierno corporativo
El ISS Governance QualityScore de Intra-Cellular Therapies, Inc., a día 29 de abril de 2024, es 7. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 7; Compensación: 7.
